

In the claims:

1-28. (Presently canceled)

29. (New): An isolated nucleic acid molecule selected from the group consisting of:

a) a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, the cDNA insert of the plasmid deposited with the ATCC as Accession Number 98820, or a complement thereof; and

b) a nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, an amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 98820;

30. (New): The nucleic acid molecule of claim 29 further comprising vector nucleic acid sequences.

31. (New): The nucleic acid molecule of claim 29 further comprising nucleic acid sequences encoding a heterologous polypeptide.

32. (New): A host cell which contains the nucleic acid molecule of claim 29.

33. (New): The host cell of claim 32 which is a mammalian host cell.

34. (New): A non-human mammalian host cell containing the nucleic acid molecule of claim 33.

35. (New): An isolated polypeptide selected from the group consisting of:

a) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 85% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6 or a complement thereof; and

b) a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 98820.

36. (New): The polypeptide of claim 35 further comprising heterologous amino acid sequences.
37. (New): An antibody which selectively binds to a polypeptide of claim 35.
38. (New): A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5, or an amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC as Accession Number 98820, comprising culturing the host cell of claim 32 under conditions in which the nucleic acid molecule is expressed.
39. (New): A method for detecting the presence of a polypeptide of claim 35 in a sample, comprising:
- a) contacting the sample with a compound which selectively binds to a polypeptide of claim 35; and
 - b) determining whether the compound binds to the polypeptide in the sample.
40. (New): The method of claim 39, wherein the compound which binds to the polypeptide is an antibody.
41. (New): A kit comprising a compound which selectively binds to a polypeptide of claim 35 and instructions for use.
42. (New): A method for detecting the presence of a nucleic acid molecule of claim 29 in a sample, comprising the steps of:
- a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule; and
 - b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample.
43. (New): The method of claim 42, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.

44. (New): A method for identifying a compound which binds to a polypeptide of claim 35 comprising the steps of:

- a) contacting a polypeptide, or a cell expressing a polypeptide of claim 35 with a test compound; and
- b) determining whether the polypeptide binds to the test compound.

45. (New): A method for identifying a compound which modulates the activity of a polypeptide of claim 35, comprising:

- a) contacting a polypeptide of claim 35 with a test compound; and
- b) determining the effect of the test compound on the activity of the polypeptide to thereby identify a compound which modulates the activity of the polypeptide.

46. (New): A method comprising:

- a) exposing a test compound to a cell encoding TANGO-93;
 - b) determining the effect of the test compound on TANGO-93 activity or expression;
- and
- c) identifying a compound that reduces TANGO-93 expression as a candidate compound for treating an inflammatory disorder.

47. (New): A method comprising administering a test compound identified in claim 46 a candidate treatment for an inflammatory disorder to a non-human mammal that is a model of an inflammatory disorder and assessing the effect of the compound on the inflammatory disorder.

48. (New): The method of claim 47 wherein the inflammatory disorder is selected from the group consisting of rheumatoid arthritis and ulcerative colitis.